vs

Side-by-side financial comparison of Insight Molecular Diagnostics Inc. (IMDX) and Iveda Solutions, Inc. (IVDA). Click either name above to swap in a different company.

Insight Molecular Diagnostics Inc. is the larger business by last-quarter revenue ($1.1M vs $626.0K, roughly 1.8× Iveda Solutions, Inc.). Iveda Solutions, Inc. runs the higher net margin — -258.6% vs -2015.4%, a 1756.8% gap on every dollar of revenue. On growth, Insight Molecular Diagnostics Inc. posted the faster year-over-year revenue change (-23.4% vs -64.1%). Over the past eight quarters, Insight Molecular Diagnostics Inc.'s revenue compounded faster (154.4% CAGR vs 34.4%).

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Iveda Solutions, Inc. is a technology provider specializing in cloud-based AI video surveillance, IoT-enabled smart sensing, and integrated smart city solutions. It serves public sector, enterprise, and education clients across North America and Asia, with core offerings covering remote security monitoring, smart facility management, and real-time data analysis tools for public safety use cases.

IMDX vs IVDA — Head-to-Head

Bigger by revenue
IMDX
IMDX
1.8× larger
IMDX
$1.1M
$626.0K
IVDA
Growing faster (revenue YoY)
IMDX
IMDX
+40.7% gap
IMDX
-23.4%
-64.1%
IVDA
Higher net margin
IVDA
IVDA
1756.8% more per $
IVDA
-258.6%
-2015.4%
IMDX
Faster 2-yr revenue CAGR
IMDX
IMDX
Annualised
IMDX
154.4%
34.4%
IVDA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IMDX
IMDX
IVDA
IVDA
Revenue
$1.1M
$626.0K
Net Profit
$-23.0M
$-1.6M
Gross Margin
42.5%
3.6%
Operating Margin
-2057.5%
-262.7%
Net Margin
-2015.4%
-258.6%
Revenue YoY
-23.4%
-64.1%
Net Profit YoY
31.5%
-7.1%
EPS (diluted)
$-0.75
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IMDX
IMDX
IVDA
IVDA
Q4 25
$1.1M
$626.0K
Q3 25
$260.0K
$1.7M
Q2 25
$518.0K
$1.5M
Q1 25
$2.1M
$1.5M
Q4 24
$1.5M
$1.7M
Q3 24
$115.0K
$2.4M
Q2 24
$104.0K
$1.5M
Q1 24
$176.0K
$346.8K
Net Profit
IMDX
IMDX
IVDA
IVDA
Q4 25
$-23.0M
$-1.6M
Q3 25
$-10.9M
$-221.3K
Q2 25
$-9.7M
$-564.2K
Q1 25
$-6.7M
$-793.7K
Q4 24
$-33.5M
$-1.5M
Q3 24
$-13.5M
$-581.4K
Q2 24
$-4.5M
$-599.0K
Q1 24
$-9.1M
$-1.3M
Gross Margin
IMDX
IMDX
IVDA
IVDA
Q4 25
42.5%
3.6%
Q3 25
53.5%
31.3%
Q2 25
67.6%
29.1%
Q1 25
62.0%
19.5%
Q4 24
40.0%
11.9%
Q3 24
43.5%
17.1%
Q2 24
48.1%
32.7%
Q1 24
25.6%
52.5%
Operating Margin
IMDX
IMDX
IVDA
IVDA
Q4 25
-2057.5%
-262.7%
Q3 25
-4249.2%
-13.0%
Q2 25
-1900.0%
-34.8%
Q1 25
-318.0%
-56.7%
Q4 24
-2262.9%
-87.3%
Q3 24
-11752.2%
-25.4%
Q2 24
-4453.8%
-39.7%
Q1 24
-5265.3%
-384.1%
Net Margin
IMDX
IMDX
IVDA
IVDA
Q4 25
-2015.4%
-258.6%
Q3 25
-4174.6%
-13.4%
Q2 25
-1880.7%
-36.9%
Q1 25
-312.0%
-53.8%
Q4 24
-2255.1%
-86.7%
Q3 24
-11733.0%
-24.2%
Q2 24
-4355.8%
-39.0%
Q1 24
-5186.9%
-371.9%
EPS (diluted)
IMDX
IMDX
IVDA
IVDA
Q4 25
$-0.75
$-0.33
Q3 25
$-0.34
$-0.07
Q2 25
$-0.30
$-0.20
Q1 25
$-0.26
$-0.28
Q4 24
$-2.19
$-0.60
Q3 24
$-0.98
$-0.27
Q2 24
$-0.36
$-0.30
Q1 24
$-1.13
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IMDX
IMDX
IVDA
IVDA
Cash + ST InvestmentsLiquidity on hand
$11.6M
$5.2M
Total DebtLower is stronger
$393.4K
Stockholders' EquityBook value
$-31.5M
$4.8M
Total Assets
$25.8M
$6.4M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IMDX
IMDX
IVDA
IVDA
Q4 25
$11.6M
$5.2M
Q3 25
$18.7M
$3.3M
Q2 25
$24.3M
$1.6M
Q1 25
$31.0M
$2.5M
Q4 24
$8.6M
$2.6M
Q3 24
$3.4M
$3.6M
Q2 24
$9.3M
$2.9M
Q1 24
$5.6M
$3.9M
Total Debt
IMDX
IMDX
IVDA
IVDA
Q4 25
$393.4K
Q3 25
$306.4K
Q2 25
$365.3K
Q1 25
$340.8K
Q4 24
$376.2K
Q3 24
$545.9K
Q2 24
$564.0K
Q1 24
$480.0K
Stockholders' Equity
IMDX
IMDX
IVDA
IVDA
Q4 25
$-31.5M
$4.8M
Q3 25
$-9.2M
$3.8M
Q2 25
$1.1M
$1.5M
Q1 25
$10.2M
$1.7M
Q4 24
$-12.3M
$2.5M
Q3 24
$9.7M
$4.1M
Q2 24
$22.7M
$2.8M
Q1 24
$11.6M
$3.3M
Total Assets
IMDX
IMDX
IVDA
IVDA
Q4 25
$25.8M
$6.4M
Q3 25
$43.9M
$5.8M
Q2 25
$50.5M
$4.4M
Q1 25
$60.4M
$4.5M
Q4 24
$35.1M
$5.2M
Q3 24
$70.2M
$9.1M
Q2 24
$74.7M
$6.8M
Q1 24
$71.0M
$6.6M
Debt / Equity
IMDX
IMDX
IVDA
IVDA
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.25×
Q1 25
0.20×
Q4 24
0.15×
Q3 24
0.13×
Q2 24
0.20×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IMDX
IMDX
IVDA
IVDA
Operating Cash FlowLast quarter
$-5.5M
$-252.4K
Free Cash FlowOCF − Capex
$-7.0M
FCF MarginFCF / Revenue
-616.7%
Capex IntensityCapex / Revenue
129.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-25.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IMDX
IMDX
IVDA
IVDA
Q4 25
$-5.5M
$-252.4K
Q3 25
$-4.5M
$-317.0K
Q2 25
$-6.3M
$-1.3M
Q1 25
$-5.9M
$-126.0K
Q4 24
$-5.4M
$-889.8K
Q3 24
$-5.5M
$-1.2M
Q2 24
$-6.0M
$-999.7K
Q1 24
$-3.8M
$-1.3M
Free Cash Flow
IMDX
IMDX
IVDA
IVDA
Q4 25
$-7.0M
Q3 25
$-5.6M
Q2 25
$-6.6M
Q1 25
$-6.2M
Q4 24
$-5.6M
$-889.8K
Q3 24
$-5.6M
$-1.5M
Q2 24
$-6.2M
$-1.1M
Q1 24
$-3.9M
$-1.5M
FCF Margin
IMDX
IMDX
IVDA
IVDA
Q4 25
-616.7%
Q3 25
-2135.4%
Q2 25
-1279.5%
Q1 25
-288.4%
Q4 24
-374.5%
-51.1%
Q3 24
-4884.3%
-64.1%
Q2 24
-5931.7%
-72.6%
Q1 24
-2189.8%
-427.3%
Capex Intensity
IMDX
IMDX
IVDA
IVDA
Q4 25
129.9%
Q3 25
403.8%
Q2 25
67.4%
Q1 25
14.4%
Q4 24
14.4%
0.0%
Q3 24
75.7%
12.5%
Q2 24
183.7%
7.5%
Q1 24
13.6%
54.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons